Basic Information
| LncRNA/CircRNA Name | lncRNA-CTS |
| Synonyms | NR_038940.1 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | cervical cancer tissues, CC cell lines (HeLa, SiHa, Ca-Ski, C-33A, and HT-3) |
| Expression Pattern | up-regulated |
| Function Description | In vitro and in vivo experiments, along with gain- and loss-of-function studies, showed that lncRNA-CTS enhanced cell migration, invasion, and the transforming growth factor (TGF)-?1-induced-EMT process. Data also showed that lncRNA-CTS could function as a competing endogenous RNA for miR-505 in CC cells. Further investigations disclosed that ZEB2 was demonstrated as a downstream target of miR-505, and subsequently exerted its metastatic effects via the lncRNA-CTS/miR-505/ZEB2 axis in CC cells. Finally, lncRNACTS activated the SMAD/TGF pathway via miR-505 in CC cells. Collectively, |
| Pubmed ID | 31499118 |
| Year | 2019 |
| Title | LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer |
External Links
| Links for lncRNA-CTS | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |